Pirche announced a collaboration with Natera to connect pre-transplant risk stratification with post-transplant monitoring using Natera’s Prospera dd-cfDNA test. The companies plan to combine Pirche’s TxPredictor platform outputs with Prospera readouts to support immunosuppression tailoring and graft longevity strategies. The partnership is intended to provide transplant teams a more unified view of a patient’s immune status over the transplant journey, spanning risk before transplant and monitoring afterward. The agreement begins with activities at the 2026 American Transplant Congress, with the companies aiming to demonstrate the clinical workflow value of combining predictive scoring and circulating biomarker monitoring. For the transplant diagnostics market, it adds another example of how dd-cfDNA testing is being paired with computational risk models to strengthen clinical decision support around rejection surveillance and treatment adjustments.